Kura Oncology (NASDAQ:KURA) Shares Gap Down – Here’s Why

Posted by Francis Steltz on May 13th, 2026

Kura Oncology, Inc. (NASDAQ:KURA – Get Free Report)’s stock price gapped down before the market opened on Wednesday . The stock had previously closed at $9.68, but opened at $8.97. Kura Oncology shares last traded at $8.8550, with a volume of 238,894 shares trading hands.

Wall Street Analyst Weigh In

A number of brokerages have commented on KURA. Zacks Research upgraded Kura Oncology from a “strong sell” rating to a “hold” rating in a report on Thursday, February 26th. HC Wainwright restated a “buy” rating and set a $40.00 price objective on shares of Kura Oncology in a report on Tuesday, January 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Kura Oncology in a report on Tuesday, April 21st. Leerink Partners set a $20.00 price objective on Kura Oncology and gave the stock an “outperform” rating in a report on Tuesday, January 13th. Finally, Wedbush decreased their price objective on Kura Oncology from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, March 6th. Ten analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Kura Oncology currently has an average rating of “Moderate Buy” and a consensus target price of $26.38.

View Our Latest Stock Analysis on KURA

Kura Oncology Stock Down 2.2%

The firm has a market cap of $840.56 million, a price-to-earnings ratio of -2.98 and a beta of 0.32. The company has a quick ratio of 6.05, a current ratio of 6.06 and a debt-to-equity ratio of 0.06. The firm has a fifty day moving average price of $8.84 and a 200-day moving average price of $9.46.

Kura Oncology (NASDAQ:KURA – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.83) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.88) by $0.05. Kura Oncology had a negative return on equity of 102.59% and a negative net margin of 412.95%.The firm had revenue of $18.27 million for the quarter, compared to analysts’ expectations of $25.97 million. As a group, sell-side analysts forecast that Kura Oncology, Inc. will post -3.36 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Suvretta Capital Management LLC boosted its holdings in Kura Oncology by 5.7% in the fourth quarter. Suvretta Capital Management LLC now owns 8,575,422 shares of the company’s stock valued at $89,099,000 after acquiring an additional 459,422 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Kura Oncology by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 5,507,627 shares of the company’s stock valued at $57,224,000 after acquiring an additional 39,105 shares during the last quarter. Armistice Capital LLC raised its position in Kura Oncology by 5.7% in the fourth quarter. Armistice Capital LLC now owns 4,936,000 shares of the company’s stock valued at $51,285,000 after purchasing an additional 264,000 shares during the period. State Street Corp raised its position in Kura Oncology by 47.5% in the fourth quarter. State Street Corp now owns 4,931,090 shares of the company’s stock valued at $51,234,000 after purchasing an additional 1,587,959 shares during the period. Finally, AQR Capital Management LLC raised its position in Kura Oncology by 36.6% in the fourth quarter. AQR Capital Management LLC now owns 3,062,212 shares of the company’s stock valued at $31,816,000 after purchasing an additional 820,020 shares during the period.

Kura Oncology Company Profile

(Get Free Report)

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.